Abbott Laboratories (NYSE:ABT) Belonging to the Medical sector which surged 2.05% and closed its last trading session at $42.29.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 10/19/2016. Currently, the stock has a 1 Year Price Target of $7.43.
The consensus recommendation, according to Zacks Investment research, is 1.6. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.6 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.6 and 1.63 respectively.
Abbott Laboratories on 6/30/2016 reported its EPS as $-0.03 with the analysts projecting the EPS of the stock as $0.01. The company beat the analyst EPS Estimate with the difference of $-0.04. This shows a surprise factor of -400%.
Many analysts have provided their estimated foresights on Abbott Laboratories Earnings, with 5 analysts believing the company would generate an Average Estimate of $0.03. Whereas they predicted High and Low Earnings Estimate as $0.11 and $-0.01 respectively. While in the same Quarter Previous year, the Actual EPS was $0.02.
Analysts are also projecting an Average Revenue Estimate for Abbott Laboratories as $22.61 Million in the Current Quarter. This estimate is provided by 5 analysts. The High Revenue estimate is predicted as 22.9 Million, while the Low Revenue Estimate prediction stands at 22.32 Million. The company’s last year sales total was 23.98 Million.
The Company got Upgrade by Edward Jones on 21-Jun-16 from Hold to Buy.
Insider Trades for Abbott Laboratories show that the latest trade was made on 25 Sep 2016 where Salvadori (Daniel Gesua Sive), the Officer completed a transaction type “Sell” in which 815 shares were traded at a price of $41.71.
6 Insider Sales transactions were made totaling 77759 shares traded.
7 analysts projected Price Targets for Abbott Laboratories. The analysts believe that the company stock price could grow as high as $11. The Low Price target projection by analysts is $6.12 and the Mean Price Target is $7.43.
Abbott Laboratories (NYSE:ABT) has the market capitalization of $62.36 Billion. The company rocked its 52-Week High of $46.38 on Nov 20, 2015 and touched its 52-Week Low of $36 on Jan 28, 2016. The stock has Return on Assets (ROA) of 5.6 percent. Return on Equity (ROE) stands at 10.9% and Return on Investment (ROI) of 7.7 percent.
The stock is currently showing YTD performance of -4.07 Percent. The company has Beta Value of 1.21 and ATR value of 0.76. The Weekly and Monthly Volatility stands at 1.72% and 1.54%.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.